StockData
Renalytix plc logo

Renalytix plc (RNLXY) company profile

RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF
Số liệu tài chính tới Q1 năm tài chính 2025, quý kết thúc ngày Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$3.56+0.06 (+1.57%)

Close on Oct 19, 2026Market cap $375.75MP/E –Yield –

About Renalytix

Services-Medical Laboratories, SIC 8071

Renalytix plc is an in vitro diagnostics company focused on managing kidney disease through artificial intelligence-enabled prognostic tools. The company develops and provides diagnostic services designed to assess the risk of progressive kidney function decline in adults with type 2 diabetes and early-stage chronic kidney disease. Its core offering, kidneyintelX.dkd, combines blood biomarkers with clinical algorithms to assist clinicians in identifying individuals who require early medical intervention before major organ damage occurs. The company markets its diagnostic testing services primarily to healthcare providers, primary care physicians, and clinical networks across the healthcare sector.

The company operates certified clinical laboratories in Salt Lake City, Utah, and St. Petersburg, Florida, alongside additional facilities in New York. Its commercial activities focus primarily on regional markets in the United States, including New York, Florida, and Texas. Renalytix plc is organized under the laws of England and Wales and maintains its principal executive offices in London, United Kingdom.

Summary of the business section of Renalytix's latest annual report, written by StockData.

Company profile

Company

Legal name
Renalytix plc
Headquarters
London, United Kingdom
Address
Finsgate, 5-7 Cranwood Street
Phone
44 29 2071 0570
Industry
Services-Medical Laboratories
Incorporated in
X0
Fiscal year ends
June 30
Auditor
CohnReznick, Iselin, New Jersey

Stock & identifiers

Ticker
RNLXY
Other tickers
RENXF
Former tickers
RNLX until Oct 1, 2024
Exchange
OTC
IPO date
Jul 17, 2020
Shares outstanding
331M, Nov 7, 2024
Public float
$24.71M, Dec 29, 2023
Filer category
<br>Emerging growth company
Stock splits
1-for-25 reverse, Dec 16, 2025
SEC CIK
1811115
FIGI
BBG00VPNC562
Share class FIGI
BBG00VPNC5Z0
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

Renalytix's leadership is listed in its proxy statement, last filed Nov 25, 2024.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 17, 2020
Securities offered
5,485,000
Exchange
Nasdaq
Lock-up ends (est.)
Jan 13, 2021

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?